TapImmune Inc Fund Company Profile
Information
50 North Laura Street
Jacksonville FL 32202
904-516-5436
Description
TapImmune, Inc., a clinical-stage immunotherapy company, develops peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. The company, in collaboration with Mayo Foundation for Medical Education and Research, is developing HER2/neu+, a vaccine technology, which has completed Phase I human clinical trials for the treatment of breast cancer; and Folate Receptor Alpha, a peptide epitope, which has completed Phase I clinical trials for the treatment of breast and ovarian cancer. Its products under preclinical stage include Polystart, a nucleic acid-based technology for HER2/neu+ breast cancer, colorectal cancer, ovarian cancer, and triple negative breast cancer. The company was founded in 1999 and is headquartered in Jacksonville, Florida.